REMS
Absorption: Despite poor absorption (1530%), therapeutic plasma concentrations are achieved.
Distribution: Widely distributed. CSF concentrations are 50% of plasma.
Half-Life: Neonates: 4 hr; Children (112 yr): 23 hr; Adults: 23.5 hr (↑ in renal failure).
( plasma concentrations)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | unknown | 1.52.5 hr | 4 hr |
| IV | prompt | end of infusion | 8 hr |
‡Salivary concentrations
Contraindicated in:
Use Cautiously in:
Derm: ↑sweating, acne, ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, ERYTHEMA MULTIFORME, hives, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS
Endo: changes in menstrual cycle
F and E: polydipsia
GI: diarrhea, nausea, vomiting, ↑liver enzymes, abdominal pain, anorexia, hyperbilirubinemia
GU: crystalluria, hematuria, RENAL FAILURE, renal pain
Local: pain, phlebitis, local irritation
MS: joint pain
Neuro: dizziness, headache, hallucinations, SEIZURES, trembling
Drug-drug:

Initial Genital Herpes
Chronic Suppressive Therapy for Recurrent Genital Herpes
Intermittent Therapy for Recurrent Genital Herpes
Acute Treatment of Herpes Zoster in Immunosuppressed Patients
Herpes Zoster in Immunocompetent Patients
Chickenpox
Mucosal and Cutaneous Herpes Simplex Infections in Immunosuppressed Patients
Herpes Simplex Encephalitis
Neonatal Herpes Simplex Infections
Varicella Zoster Infections in Immunosuppressed Patients
Renal Impairment
Herpes Labialis
Lab Test Considerations:
IV Administration:
NDC Code